Protagonist Therapeutics Share Price Today
(NASDAQ: PTGX)

Name: Protagonist Therapeutics Share Price Today (NASDAQ: PTGX) - Protagonist Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Protagonist Therapeutics share price is $37.8 & ₹3,274.99 as on 1 Feb 2025, 2.30 'hrs' IST

$37.8

▲

-1.32

(-3.37%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Protagonist Therapeutics share price in Dollar and Rupees. Guide to invest in Protagonist Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Protagonist Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Protagonist Therapeutics share price movements

Today's Low: $37.64
Today's High: $39.64
$37.80
0.42%
Downside
Day's Volatility :5.05%
Upside
4.64%
52 Weeks Low: $24.22
52 Weeks High: $48.89
$37.80
35.93%
Downside
52 Weeks Volatility :50.46%
Upside
22.68%

Protagonist Therapeutics (PTGX) Returns

Period	Protagonist Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-19.16%	-0.6%	0.0%
6 Months	5.62%	-2.8%	0.0%
1 Year	45.33%	3.3%	0.0%
3 Years	30.57%	11.6%	-13.7%

Protagonist Therapeutics (PTGX) Key Statistics

in dollars & INR

Previous Close	$39.12
Open	$38.92
Today's High	$39.64
Today's Low	$37.64
Market Capitalization	$2.3B
Today's Volume	$605.9K
52 Week High	$48.89
52 Week Low	$24.22
Revenue TTM	$323.8M
EBITDA	$150.1M
Earnings Per Share (EPS)	$2.74
PE Ratio	14.28
Profit Margin	52.77%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	40.97%

How to invest in Protagonist Therapeutics Stock (PTGX) from India?

It is very easy for Indian residents to invest directly in Protagonist Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Protagonist Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Protagonist Therapeutics or PTGX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Protagonist Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Protagonist Therapeutics shares which would translate to 0.023 fractional shares of Protagonist Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Protagonist Therapeutics, in just a few clicks!

Returns in Protagonist Therapeutics (PTGX) for Indian investors in Rupees

The Protagonist Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Protagonist Therapeutics investment value today

Current value as on today

₹1,49,888

Returns

₹49,888

(+49.89%)

Returns from Protagonist Therapeutics Stock

₹45,329 (+45.33%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Protagonist Therapeutics (PTGX)

-70%

Period: Jan 2, 2025 to Feb 1, 2025. Change in 30 Days versus previous period

Search interest for Protagonist Therapeutics Stock from India on INDmoney has decreased by -70% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Protagonist Therapeutics

BlackRock Inc
17.16%
Farallon Capital Management, L.L.C.
9.83%
RTW INVESTMENTS, LLC
9.10%
Vanguard Group Inc
7.07%
State Street Corp
5.34%
Johnson & Johnson
4.11%

Analyst Recommendation on Protagonist Therapeutics

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Protagonist Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Protagonist Therapeutics Stock (PTGX)

What analysts predicted

Upside of 51.06%

Target:

$57.10

Current:

$37.80

Insights on Protagonist Therapeutics Stock (Ticker Symbol: PTGX)

Price Movement
In the last 3 months, PTGX stock has moved down by -19.2%
PTGX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 22.6%
PTGX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 62.2%
Price to Sales
ForPTGX every $1 of sales, investors are willing to pay $7.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

Protagonist Therapeutics Technicals Summary

Sell

Neutral

Buy

Protagonist Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Protagonist Therapeutics (PTGX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Protagonist Therapeutics Inc	-3.03%	5.62%	45.33%	30.57%	373.68%
Biontech Se	7.35%	57.95%	32.59%	-29.28%	275.97%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.13%	8.42%	89.04%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	7.65%	89.41%	92.64%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	58.94%	90.38%	126.17%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Protagonist Therapeutics Inc	14.28	14.28	0.0	2.53	0.41	0.2	NA	8.94
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Protagonist Therapeutics Inc	Buy	$2.3B	373.68%	14.28	52.77%
Biontech Se	Buy	$29.0B	275.97%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	89.04%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	92.64%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	126.17%	NA	-15.86%

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Organization	Protagonist Therapeutics
Employees	126
CEO	Dr. Dinesh V. Patel Ph.D.
Industry	Health Technology

Management People of Protagonist Therapeutics

Name	Title
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director
Mr. Asif Ali	Executive VP & Chief Financial Officer
Dr. Suneel K. Gupta Ph.D.	Executive VP of Clinical Development
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & Chief Technical Officer
Dr. Newman Yeilding	EVP, Chief Scientific Officer
Mr. Matthew M. Gosling J.D.	Executive VP & General Counsel
Ms. Carena Spivey	Head of HR & Senior VP of Human Resources
Dr. Ashok Bhandari Ph.D.	Executive VP & Chief Drug Discovery and Preclinical Development Officer
Mr. Carter J. King	Executive Vice President of Business Development
Ms. Abha Bommireddi	Executive Vice President of Portfolio & Program Management

Important FAQs about investing in PTGX Stock from India :

What is Protagonist Therapeutics share price today?

Protagonist Therapeutics share price today stands at $37.80, Open: $38.92 ; Previous Close: $39.12 ; High: $39.64 ; Low: $37.64 ; 52 Week High: $48.89 ; 52 Week Low: $24.22.

The stock opens at $38.92, after a previous close of $39.12. The stock reached a daily high of $39.64 and a low of $37.64, with a 52-week high of $48.89 and a 52-week low of $24.22.

Can Indians buy Protagonist Therapeutics shares?

Yes, Indians can invest in the Protagonist Therapeutics (PTGX) from India.

With INDmoney, you can buy Protagonist Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Protagonist Therapeutics at zero transaction cost.

How can I buy Protagonist Therapeutics shares from India?

It is very easy to buy Protagonist Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Protagonist Therapeutics (PTGX) be purchased?

Yes, you can buy fractional shares of Protagonist Therapeutics with INDmoney app.

What are the documents required to start investing in Protagonist Therapeutics stocks?

To start investing in Protagonist Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.